FemmePharma Global Healthcare is focused on developing safe and effective drugs minimizing or eliminating the side effects associated with many drug therapies by designing treatments in a way that suits the female anatomy and physiology. The company has already scored great success in the development of a treatment for endometriosis through Phase 2. As a result, KV Pharmaceuticals bought the global rights and continues its development of the product. Other current endeavors include a product to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development
